435 related articles for article (PubMed ID: 9342447)
1. Pharmacokinetics of oral morphine sulfate in dogs: a comparison of sustained release and conventional formulations.
Dohoo SE; Tasker RA
Can J Vet Res; 1997 Oct; 61(4):251-5. PubMed ID: 9342447
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of parenteral and oral sustained-release morphine sulphate in dogs.
Dohoo S; Tasker RA; Donald A
J Vet Pharmacol Ther; 1994 Dec; 17(6):426-33. PubMed ID: 7707487
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of an immediate and extended release oral morphine formulation utilizing the spheroidal oral drug absorption system in dogs.
Aragon CL; Read MR; Gaynor JS; Barnhart MD; Wilson D; Papich MG
J Vet Pharmacol Ther; 2009 Apr; 32(2):129-36. PubMed ID: 19290942
[TBL] [Abstract][Full Text] [Related]
4. Does intraosseous equal intravenous? A pharmacokinetic study.
Von Hoff DD; Kuhn JG; Burris HA; Miller LJ
Am J Emerg Med; 2008 Jan; 26(1):31-8. PubMed ID: 18082778
[TBL] [Abstract][Full Text] [Related]
5. In vivo evaluation of a new sustained-release formulation of morphine.
Araico A; Saadeddin A; Torres-Molina F; Peris JE
Pharmazie; 2009 Oct; 64(10):653-5. PubMed ID: 19947167
[TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetics of oral sustained-release morphine sulphate in dogs.
Dohoo S
J Vet Pharmacol Ther; 1997 Apr; 20(2):129-33. PubMed ID: 9131539
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
Göhler K; Brett M; Smit JW; Rengelshausen J; Terlinden R
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):338-48. PubMed ID: 23357834
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of buprenorphine following intravenous administration in dogs.
Krotscheck U; Boothe DM; Little AA
Am J Vet Res; 2008 Jun; 69(6):722-7. PubMed ID: 18518651
[TBL] [Abstract][Full Text] [Related]
9. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of morphine and plasma concentrations of morphine-6-glucuronide following morphine administration to dogs.
KuKanich B; Lascelles BD; Papich MG
J Vet Pharmacol Ther; 2005 Aug; 28(4):371-6. PubMed ID: 16050817
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
[TBL] [Abstract][Full Text] [Related]
12. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
13. [Bioavailability of morphine after oral administration as retard tablets].
Dittrich P; Semmelrock J; Wolf G; Beubler E
Wien Klin Wochenschr; 1996; 108(5):147-52. PubMed ID: 8901129
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
[TBL] [Abstract][Full Text] [Related]
15. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.
Gourlay GK
Clin Pharmacokinet; 1998 Sep; 35(3):173-90. PubMed ID: 9784932
[TBL] [Abstract][Full Text] [Related]
16. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
17. [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
Yang XG; Nie SF; Bai HJ; Zhang GJ; Pan WS
Yao Xue Xue Bao; 2005 May; 40(5):457-61. PubMed ID: 16220793
[TBL] [Abstract][Full Text] [Related]
18. Comparison of gastroretentive microspheres and sustained-release preparations using theophylline pharmacokinetics.
Miyazaki Y; Yakou S; Takayama K
J Pharm Pharmacol; 2008 Jun; 60(6):693-8. PubMed ID: 18498704
[TBL] [Abstract][Full Text] [Related]
19. Effects of ketoconazole on the pharmacokinetics and pharmacodynamics of morphine in healthy Greyhounds.
Kukanich B; Borum SL
Am J Vet Res; 2008 May; 69(5):664-9. PubMed ID: 18447799
[TBL] [Abstract][Full Text] [Related]
20. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2003 Dec; 74(6):543-54. PubMed ID: 14663457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
